Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Christine Montoto-Grillot"'
Autor:
Adrien Buisson, Pierre Saintigny, Eric Pujade-Lauraine, Christine Montoto-Grillot, Davide Vacirca, Massimo Barberis, Nicoletta Colombo, Alexandre Harle, Pauline Gilson, Cristin Roma, Francesca Bergantino, Philipp Harter, Sandro Pignata, Antonio Gonzalez Martin, Christian Schauer, Keiichi Fujiwara, Ignace Vergote, Trine Jakobi Nøttrup, Pierre-Alexandre Just, Isabelle Laure Ray-Coquard
Publikováno v:
Journal of Clinical Oncology. 40:e17599-e17599
e17599 Background: Poly (ADP-ribose) polymerase inhibitors (PARPi) induce synthetic lethality in cells with homologous recombination deficiency (HRD). PARPi treatment revolutionized management of patients with cancer, particularly in types where HRD
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::120e076519cbf1ba40fd1ae68a4c088b
https://doi.org/10.1200/jco.2022.40.16_suppl.e17599
https://doi.org/10.1200/jco.2022.40.16_suppl.e17599
Autor:
Jean-Pierre Gérard, David Azria, Sophie Gourgou-Bourgade, Isabelle Martel-Laffay, Christophe Hennequin, Pierre-Luc Etienne, Véronique Vendrely, Eric François, Guy de La Roche, Olivier Bouché, Xavier Mirabel, Bernard Denis, Laurent Mineur, Jean-François Berdah, Marc André Mahé, Yves Bécouarn, Olivier Dupuis, Gérard Lledo, Christine Montoto-Grillot, Thierry Conroy
Publikováno v:
Journal of Clinical Oncology. 28:1638-1644
Purpose Neoadjuvant chemoradiotherapy is considered a standard approach for T3-4 M0 rectal cancer. In this situation, we compared neoadjuvant radiotherapy plus capecitabine with dose-intensified radiotherapy plus capecitabine and oxaliplatin. Patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0faf8993d944c63beb7cb52e2e7a98a7
https://doi.org/10.1200/jco.2009.25.8376
https://doi.org/10.1200/jco.2009.25.8376
Autor:
Thierry, Conroy, Françoise, Desseigne, Marc, Ychou, Olivier, Bouché, Rosine, Guimbaud, Yves, Bécouarn, Antoine, Adenis, Jean-Luc, Raoul, Sophie, Gourgou-Bourgade, Christelle, de la Fouchardière, Jaafar, Bennouna, Jean-Baptiste, Bachet, Faiza, Khemissa-Akouz, Denis, Péré-Vergé, Catherine, Delbaldo, Eric, Assenat, Bruno, Chauffert, Pierre, Michel, Christine, Montoto-Grillot, Michel, Ducreux, C, Platini
Publikováno v:
New England Journal of Medicine
New England Journal of Medicine, Massachusetts Medical Society, 2011, 364 (19), pp.1817-1825
New England Journal of Medicine, Massachusetts Medical Society, 2011, 364 (19), pp.1817-1825
BACKGROUND Data are lacking on the efficacy and safety of a combination chemotherapy regimen consisting of oxaliplatin, irinotecan, fluorouracil, and leucovorin (FOLFIRINOX) as compared with gemcitabine as first-line therapy in patients with metastat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2370ece8c2f3366be324a23e92de0e3b
https://hal.archives-ouvertes.fr/hal-00598658
https://hal.archives-ouvertes.fr/hal-00598658
